# Biotech Daily Digest — 2026-01-30

**27 items from 4 sources**

## Summary by Source

- Endpoints News: 5 items
- Fierce Biotech: 6 items
- Regeneron Press Releases: 1 item
- arXiv q-bio: 15 items


## Endpoints News

- **[AstraZeneca pays $1.2B for CSPC's long-acting obesity drugs](https://endpoints.news/astrazeneca-pays-1-2b-for-cspcs-long-acting-obesity-drugs/)**  
  _Fri, 30 Jan 2026 10:36:16 +0000_  
  AstraZeneca is already delivering on its $15 billion commitment to China with a $1.2 billion upfront pact with CSPC Pharmaceutical, spanning eight drug programs and multiple platform technologies.

 On Thursday, the UK ...

- **[Takeda is ‘not in favor’ of Trump’s MFN deals, CEO-designate says](https://endpoints.news/takeda-is-not-in-favor-of-trumps-mfn-deals-ceo-designate-says/)**  
  _Thu, 29 Jan 2026 18:01:01 +0000_  
  Takeda’s incoming CEO took a firm stance against President Donald Trump’s “most favored nation” deals with drugmakers on Thursday, while Sanofi and Roche shared new details about their negotiations with the White House.

 “In general ...

- **[Sanofi vows to stay committed to vaccines as portfolio takes a hit](https://endpoints.news/sanofi-vows-to-stay-committed-to-vaccines-as-portfolio-takes-a-hit/)**  
  _Thu, 29 Jan 2026 16:18:36 +0000_  
  Sanofi CEO Paul Hudson emphasized the company’s commitment to vaccine development in the face of an increasingly challenging sales environment and its decision to abandon an mRNA-based flu vaccine program.

 “We have to continue to ...

- **[Summit gets November PDUFA date for its PD-1xVEGF bispecific](https://endpoints.news/summit-gets-november-pdufa-date-for-its-pd-1xvegf-bispecific/)**  
  _Thu, 29 Jan 2026 15:07:25 +0000_  
  The leader in the next frontier of immuno-oncology officially has a date with the FDA.

 Summit Therapeutics announced Thursday morning that US regulators have accepted its submission package for the experimental drug ivonescimab, a bispecific ...

- **[Updated: Roche predicts its breast cancer pill could become its biggest-selling drug](https://endpoints.news/roche-predicts-its-breast-cancer-pill-could-become-its-biggest-selling-drug/)**  
  _Thu, 29 Jan 2026 12:11:54 +0000_  
  With two positive clinical readouts in the bag, a US approval filing, and another important trial due to report in a couple months, Roche’s breast cancer drug giredestrant is sitting pretty.

 Management is hugely confident ...


## Fierce Biotech

- **[<a href="https://www.fiercebiotech.com/biotech/amgen-jilts-kyowa-exiting-400m-autoimmune-pact-after-running-vast-pivotal-program" hreflang="en">Amgen jilts Kyowa, exiting $400M autoimmune pact after running vast pivotal program </a>](https://www.fiercebiotech.com/biotech/amgen-jilts-kyowa-exiting-400m-autoimmune-pact-after-running-vast-pivotal-program)**  
  _Jan 30, 2026 8:55am_  
  Amgen has terminated its rocatinlimab collaboration with Kyowa Kirin, walking away from the anti-OX40 antibody five years after paying $400 million for rights to the autoimmune disease drug candidate.

- **[<a href="https://www.fiercebiotech.com/biotech/astrazeneca-returns-chinas-cspc-47b-obesity-deal" hreflang="en">AstraZeneca returns to China's CSPC for $18.5B obesity deal</a>](https://www.fiercebiotech.com/biotech/astrazeneca-returns-chinas-cspc-47b-obesity-deal)**  
  _Jan 30, 2026 4:51am_  
  The ink was barely dry on AstraZeneca’s announcement of a landmark investment in its Chinese capabilities before the U.K.-based pharma agreed to pay more than $1 billion to one of its regional partners.

- **[<a href="https://www.fiercebiotech.com/biotech/moderna-offloads-late-stage-rare-disease-drug-recordati-50m-upfront" hreflang="en">Moderna offloads late-stage rare disease drug to Recordati for $50M upfront</a>](https://www.fiercebiotech.com/biotech/moderna-offloads-late-stage-rare-disease-drug-recordati-50m-upfront)**  
  _Jan 30, 2026 4:15am_  
  Moderna has out-licensed a rare disease drug candidate to Recordati, accepting $50 million upfront for an asset that could deliver registrational data this year.

- **[<a href="https://www.fiercebiotech.com/biotech/formation-bios-china-shopping-spree-continues-500m-biobucks-autoimmune-pact" hreflang="en">Formation Bio’s China shopping spree continues with $500M biobucks autoimmune pact</a>](https://www.fiercebiotech.com/biotech/formation-bios-china-shopping-spree-continues-500m-biobucks-autoimmune-pact)**  
  _Jan 29, 2026 12:20pm_  
  AI-fueled Formation Bio has inked another licensing deal for a China asset, this time picking up an oral small molecule designed to treat autoimmune disease in a deal worth up to $500 million biobucks.

- **[<a href="https://www.fiercebiotech.com/biotech/sanofi-scraps-attempt-develop-next-gen-mrna-seasonal-flu-vaccine" hreflang="en">Sanofi abandons attempt to develop next-gen mRNA seasonal flu vaccine</a>](https://www.fiercebiotech.com/biotech/sanofi-scraps-attempt-develop-next-gen-mrna-seasonal-flu-vaccine)**  
  _Jan 29, 2026 9:38am_  
  Two and a half years after Sanofi unveiled to investors a revamped strategy to create an mRNA seasonal flu vaccine, Fierce Biotech has learned that the French pharma has put this pipeline on ice.

- **[<a href="https://www.fiercebiotech.com/biotech/belgium-biotech-agomab-outlines-212m-nasdaq-debut" hreflang="en">Belgium biotech Agomab outlines up to $212M Nasdaq debut to fund immunology trials</a>](https://www.fiercebiotech.com/biotech/belgium-biotech-agomab-outlines-212m-nasdaq-debut)**  
  _Jan 29, 2026 10:14am_  
  Immunology biotech Agomab Therapeutics is seeking to raise up to $212.5 million in its Nasdaq debut, joining a series of biotechs chipping away at 2025’s iced-over IPO market.


## Regeneron Press Releases

- **[Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results](https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-fourth-quarter-and-full-year-2025-financial)**  
  _Fri, 30 Jan 2026 06:30:00 -0500_  
  Fourth quarter 2025 revenues increased 3% to $3.9 billion versus fourth quarter 2024; full year 2025 revenues increased 1% to $14.3 billion versus 2024 Fourth quarter 2025 Dupixent ® global net sales   (recorded by Sanofi) increased 34% to $4.9 billion versus fourth quarter 2024; full year 2025


## arXiv q-bio

- **[Integrating Color Histogram Analysis and Convolutional Neural Network for Skin Lesion Classification](https://arxiv.org/abs/2601.20869)**  
  _Fri, 30 Jan 2026 00:00:00 -0500_  
  arXiv:2601.20869v1 Announce Type: new 
Abstract: The color of skin lesions is an important diagnostic feature for identifying malignant melanoma and other skin diseases. Typical colors associated with melanocytic lesions include tan, brown, black, red, white, and blue gray. This study introduces a novel feature: the n…

- **[Log Focal Frequency Loss for Bioimage Restoration](https://arxiv.org/abs/2601.20878)**  
  _Fri, 30 Jan 2026 00:00:00 -0500_  
  arXiv:2601.20878v1 Announce Type: new 
Abstract: Image restoration of biological structures in microscopy poses unique challenges for preserving fine textures and sharp edges. While recent GAN-based image restoration formulations have introduced frequency-domain losses for natural images, microscopy images pose distin…

- **[ATTNSOM: Learning Cross-Isoform Attention for Cytochrome P450 Site-of-Metabolism](https://arxiv.org/abs/2601.20891)**  
  _Fri, 30 Jan 2026 00:00:00 -0500_  
  arXiv:2601.20891v1 Announce Type: new 
Abstract: Identifying metabolic sites where cytochrome P450 enzymes metabolize small-molecule drugs is essential for drug discovery. Although existing computational approaches have been proposed for site-of-metabolism prediction, they typically ignore cytochrome P450 isoform iden…

- **[Long-term evolution of regulatory DNA sequences. Part 2: Theory and future challenges](https://arxiv.org/abs/2601.21480)**  
  _Fri, 30 Jan 2026 00:00:00 -0500_  
  arXiv:2601.21480v1 Announce Type: new 
Abstract: Promoters and enhancers are cis-regulatory elements (CREs), DNA sequences that bind transcription factor (TF) proteins to up- or down-regulate target genes. Decades-long efforts yielded TF-DNA interaction models that predict how strongly an individual TF binds arbitrary…

- **[How 'Neural' is a Neural Foundation Model?](https://arxiv.org/abs/2601.21508)**  
  _Fri, 30 Jan 2026 00:00:00 -0500_  
  arXiv:2601.21508v1 Announce Type: new 
Abstract: Foundation models have shown remarkable success in fitting biological visual systems; however, their black-box nature inherently limits their utility for understanding brain function. Here, we peek inside a SOTA foundation model of neural activity (Wang et al., 2025) as…

- **[Computational investigation of single herbal drugs in Ayurveda for diabetes and obesity using knowledge graph and network pharmacology](https://arxiv.org/abs/2601.21643)**  
  _Fri, 30 Jan 2026 00:00:00 -0500_  
  arXiv:2601.21643v1 Announce Type: new 
Abstract: Metabolic diseases such as type 2 diabetes and obesity represent a rapidly escalating global health burden, yet current therapeutic strategies largely target isolated symptoms or single molecular pathways. To this end, we developed an integrated computational pipeline l…

- **[Diversifying Toxicity Search in Large Language Models Through Speciation](https://arxiv.org/abs/2601.20981)**  
  _Fri, 30 Jan 2026 00:00:00 -0500_  
  arXiv:2601.20981v1 Announce Type: cross 
Abstract: Evolutionary prompt search is a practical black-box approach for red teaming large language models (LLMs), but existing methods often collapse onto a small family of high-performing prompts, limiting coverage of distinct failure modes. We present a speciated quality-d…

- **[Multiple binding modes of AKT on PIP$_3$-containing membranes](https://arxiv.org/abs/2601.21216)**  
  _Fri, 30 Jan 2026 00:00:00 -0500_  
  arXiv:2601.21216v1 Announce Type: cross 
Abstract: The PI3K/AKT signaling pathway is triggered by recruitment of AKT to cellular membranes. Although AKT is a multidomain serine/threonine kinase composed of an N-terminal pleckstrin homology (PH) domain and a C-terminal kinase domain, how these domains cooperate to regu…

- **[BrainFuse: a unified infrastructure integrating realistic biological modeling and core AI methodology](https://arxiv.org/abs/2601.21407)**  
  _Fri, 30 Jan 2026 00:00:00 -0500_  
  arXiv:2601.21407v1 Announce Type: cross 
Abstract: Neuroscience and artificial intelligence represent distinct yet complementary pathways to general intelligence. However, amid the ongoing boom in AI research and applications, the translational synergy between these two fields has grown increasingly elusive-hampered b…

- **[Impact of behavioral heterogeneity on epidemic outcome and its mapping into effective network topologies](https://arxiv.org/abs/2601.21743)**  
  _Fri, 30 Jan 2026 00:00:00 -0500_  
  arXiv:2601.21743v1 Announce Type: cross 
Abstract: Human behavior plays a critical role in shaping epidemic trajectories. During health crises, people respond in diverse ways in terms of self-protection and adherence to recommended measures, largely reflecting differences in how individuals assess risk. This behaviora…

- **[The Patient is not a Moving Document: A World Model Training Paradigm for Longitudinal EHR](https://arxiv.org/abs/2601.22128)**  
  _Fri, 30 Jan 2026 00:00:00 -0500_  
  arXiv:2601.22128v1 Announce Type: cross 
Abstract: Large language models (LLMs) trained with next-word-prediction have achieved success as clinical foundation models. Representations from these language backbones yield strong linear probe performance across biomedical tasks, suggesting that patient semantics emerge fr…

- **[Models of attractor dynamics in the brain](https://arxiv.org/abs/2505.01098)**  
  _Fri, 30 Jan 2026 00:00:00 -0500_  
  arXiv:2505.01098v2 Announce Type: replace 
Abstract: Attractor dynamics are a fundamental computational motif in neural circuits, supporting diverse cognitive functions through stable, self-sustaining patterns of neural activity. In these lecture notes, we review four key examples that demonstrate how autoassociative…

- **[RNAGenScape: Property-Guided, Optimized Generation of mRNA Sequences with Manifold Langevin Dynamics](https://arxiv.org/abs/2510.24736)**  
  _Fri, 30 Jan 2026 00:00:00 -0500_  
  arXiv:2510.24736v2 Announce Type: replace 
Abstract: Generating property-optimized mRNA sequences is central to applications such as vaccine design and protein replacement therapy, but remains challenging due to limited data, complex sequence-function relationships, and the narrow space of biologically viable sequence…

- **[scDataset: Scalable Data Loading for Deep Learning on Large-Scale Single-Cell Omics](https://arxiv.org/abs/2506.01883)**  
  _Fri, 30 Jan 2026 00:00:00 -0500_  
  arXiv:2506.01883v2 Announce Type: replace-cross 
Abstract: Training deep learning models on single-cell datasets with hundreds of millions of cells requires loading data from disk, as these datasets exceed available memory. While random sampling provides the data diversity needed for effective training, it is prohibit…

- **[Kinetic formulation of compartmental epidemic models](https://arxiv.org/abs/2506.13551)**  
  _Fri, 30 Jan 2026 00:00:00 -0500_  
  arXiv:2506.13551v2 Announce Type: replace-cross 
Abstract: We introduce a kinetic model that couples the movement of a population of individuals with the dynamics of a pathogen in the same population. We consider that transmission occurs when a susceptible and an infectious individual are sufficiently close for a suff…
